欧洲顶级临床试验申办方的数据共享政策调查
该研究调查了在欧洲临床试验信息系统注册试验数量排名前20的公共和前20的私立申办方,系统检索其公开网站、结构化谷歌搜索及主要数据管理计划平台,并由两名评价员独立提取数据共享政策、数据管理与共享计划及数据使用协议的存在性、可及性与内容。结果显示私立申办方更常公开试验特异性数据共享政策和使用协议,公共申办方更多引用数据管理与共享计划但异质性大且常嵌入机构治理文件。申办方验证总体应答率为37.5%。
要点
- 私立申办方更常公开试验特异性数据共享政策与数据使用协议,常通过既有数据共享平台提供。
- 公共申办方更多引用数据管理与共享计划,但范围异质且常嵌入机构治理文件而非针对临床试验。
- 各行业均强调GDPR合规、数据保护和法律保障,但数据集就绪、审查标准及下游责任等操作层面差异大。
核心结论
- 欧盟顶级临床试验申办方的数据共享治理存在明显行业失衡,私立申办方文档更详细且操作明确,公共申办方多表述高层承诺而缺乏试验特异性指导。
- 提高清晰度和标准化(尤其公共申办方)可在符合GDPR要求的同时改善透明度并促进负责任的数据再利用。
研究设计与样本
- 研究纳入按欧盟临床试验信息系统注册试验数量排名前20的公共和前20的私立申办方,共40家。
- 纳入材料为公开或申办方共享的与临床试验数据共享或管理相关的政策、指南、声明、模板和协议。
- 通过申办方公开网站系统检索、结构化谷歌搜索及主要数据管理计划平台识别证据,并直接联系申办方验证和索取缺失文档。
- 所有来源存档编目,两名评价员独立使用结构化表格提取数据共享政策、数据管理与共享计划及数据使用协议的存在性、可及性与内容。
- 定量数据描述性总结,并进行非解释性描述性内容分析以刻画反复出现的政策要素和异质性领域。
主要发现
- 40家申办方中,私立申办方比公共申办方更可能公开试验特异性数据共享政策和数据使用协议,常通过既有数据共享平台提供。
- 公共申办方更常引用数据管理与共享计划,但这些计划范围异质且常嵌入更广泛的机构治理文件而非针对临床试验定制。
- 各行业均强调GDPR合规、数据保护和法律保障,但数据集就绪、审查标准及下游责任等操作层面差异广泛。
- 申办方验证总体应答率为37.5%。
临床怎么用
- 申办方制定数据共享政策时可参考私立申办方的操作明确文档,同时确保符合GDPR要求。
- 公共申办方宜将高层数据共享承诺转化为试验特异性指导,明确数据集就绪、审查标准和下游责任。
- 研究者在寻求数据共享时需注意公共与私立申办方在政策可及性和操作细节上的差异。
局限性
- 申办方验证总体应答率为37.5%,可能影响文档完整性和验证充分性。
- 仅纳入欧盟临床试验信息系统注册试验数量排名前20的公共和前20的私立申办方,结果外推受限。
- 内容分析为非解释性描述,未评估政策执行效果或数据共享实际发生情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to map the presence, public availability, and content of clinical trial data sharing policies, data management and sharing plans, and data use agreements among the most prolific public and private clinical trial sponsors operating in Europe. STUDY DESIGN AND SETTING: We included organization-level documents describing approaches to clinical trial data sharing or data management from the top 20 public and top 20 private sponsors ranked by the number of trials registered in the European Union (EU) Clinical Trials Information System. Eligible materials comprised publicly available or sponsor-shared policies, guidelines, statements, templates, and agreements relevant to clinical trial data sharing or management. Evidence was identified through systematic searches of sponsors' public websites, structured Google searches, and major data management plan platforms, complemented by direct contact with sponsors to verify findings and request missing documentation. All sources were archived and cataloged. Two reviewers independently extracted data using a structured form, capturing the existence, accessibility, and content of data sharing policies, data management and sharing plans, and data use agreements. Quantitative data were summarized descriptively, and a noninterpretive descriptive content analysis was conducted to characterize recurring policy elements and areas of heterogeneity. RESULTS: Among 40 sponsors, private sponsors were substantially more likely than public sponsors to make trial-specific data sharing policies and data use agreements publicly accessible, often via established data sharing platforms. Public sponsors more frequently referenced data management and sharing plans, but these were heterogeneous in scope and often embedded within broader institutional governance documents rather than tailored to clinical trials. Across sectors, General Data Protection Regulation compliance, data protection, and legal safeguards were emphasized, while operational aspects such as dataset readiness, review criteria, and downstream responsibilities varied widely. Overall response rate to sponsor verification was 37.5%. CONCLUSION: Clinical trial data sharing governance in the EU shows a marked sectoral imbalance among the top sponsors. Private sponsors tend to provide more detailed and operationally explicit documentation, whereas public sponsors often articulate high-level commitments without trial-specific guidance. Greater clarity and standardization, particularly among public sponsors, could improve transparency and facilitate responsible data reuse, while remaining compatible with General Data Protection Regulation requirements.
引用
- Tai KH, Varvarà G, Escoffier E, et al. Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in Europe. J Clin Epidemiol. 2026. PMID: 42575483. doi:10.1016/j.jclinepi.2026.112452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。